Skip to main
DCPH
DCPH logo

Deciphera Pharmaceuticals (DCPH) Stock Forecast & Price Target

Deciphera Pharmaceuticals (DCPH) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 32%
Buy 32%
Hold 32%
Sell 5%
Strong Sell 0%

Bulls say

Deciphera Pharmaceuticals is expected to continue experiencing strong US sales growth due to off-label use in 2L GIST, along with price and treatment duration increases. With increased forecasts for both Qinlock sales and vimseltinib, along with a reiteration of their Buy rating and Price Target increase to $30, it is clear that analysts have a positive outlook on the company's financial performance.

Bears say

Deciphera Pharmaceuticals is facing several challenges, including declining cash reserves and a limited market presence due to contract negotiations. Additionally, their lead drug candidate has faced rejection from the EMA, adding further uncertainty to their growth potential in the near term. While they may have a chance at gaining approval for their other drug candidate in the EU market, it is still uncertain.

Deciphera Pharmaceuticals (DCPH) has been analyzed by 22 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 32% recommend Buy, 32% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Deciphera Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Deciphera Pharmaceuticals (DCPH) Forecast

Analysts have given Deciphera Pharmaceuticals (DCPH) a Buy based on their latest research and market trends.

According to 22 analysts, Deciphera Pharmaceuticals (DCPH) has a Buy consensus rating as of Jul 28, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36.24, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36.24, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Deciphera Pharmaceuticals (DCPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.